3rd line treatments in pancreatic cancer

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a recent paper by A. Gueiderikh et al. published in BMC Cancer.

“Pancreatic adenocarcinoma third line systemic treatments: a retrospective cohort study”

Authors: Gueiderikh, A., Tarabay, A., Abdelouahab, M. et al.

“3rd line treatments in pancreatic cancer

• 37% of patients could proceed to 3rd line
• mOFS: 2 mo, mOS:5.5 mo
• Erlotinib and gemcitabine monotherapy -> negative outcomes.”

Source: Erman Akkus/X